Hi TJ,
In the past 48 hours there have been a number of reports around the globe. In a previous post I noted that its a Global Medical Arms Race for a herpes vaccine.
The National Institute of Allergy and Infectious Diseases Department (US) is now funding one groups trials. Another firm is moving closer to Phase III.
I continue to ponder what the share price of AHZ would be if it solely focused on it's core product - adapt whilst seeing a growing expense on the vaccine side. And vaccine research is phenomenally expensive.
http://www.nasdaq.com/article/genoc...data-for-genital-herpes-analyst-blog-cm400399
http://www.providencejournal.com/bu...-protect-against-genital-herpes-infection.ece
http://www.nasdaq.com/press-release/vical-granted-six-us-patents-for-hsv2-vaccines-20141008-00143
Hi TJ, In the past 48 hours there have been a number of reports...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |